Breaking News

Tweet TWEET

Kathleen P. Bloch Appointed as Chief Financial Officer of CytoSorbents

Kathleen P. Bloch Appointed as Chief Financial Officer of CytoSorbents

MONMOUTH JUNCTION, N.J., May 13, 2013 (GLOBE NEWSWIRE) -- CytoSorbents
Corporation (OTCBB:CTSO), a critical care focused therapeutic device company
using blood purification to treat life-threatening illnesses, today announced
the appointment of Kathleen P. Bloch, MBA, CPA, as its Chief Financial
Officer, effective May 29, 2013.

Ms. Bloch has more than 20 years of executive financial experience in both
public and private companies.Most recently, she was Chief Financial Officer
of Laureate Biopharmaceutical Services, Inc., a leader in biopharmaceutical
contract development and manufacturing.Previously, Ms. Bloch was Chief
Operating Officer and CFO of PC Group, Inc., a $70 million in revenue,
NASDAQ-listed, publicly traded company with a diverse group of holdings,
including several medical device subsidiaries.Prior to that, Ms. Bloch was
CFO of Silver Line Building Products Corporation for seven years, helping it
grow from $100 million in sales, into the world's largest manufacturer of
vinyl windows with more than $750 million in revenue, employing over 7,000
people nationwide in 35 states with nine manufacturing facilities.In 2006,
she oversaw the acquisition of Silver Line by Andersen Corporation, a leading
international manufacturer of windows.Previously, Ms. Bloch was CFO of ERD
Waste Corporation, a NASDAQ-listed, publicly-traded environmental services
provider, operating in 16 states with more than $60 million in sales.She
began her career at Peat Marwick International, which became KPMG LLP, one of
the big four accounting firms. Ms. Bloch holds a Master of Business
Administration degree and a Bachelor of Science Accounting degree from LaSalle
University, and is a Certified Public Accountant.

Ms. Bloch commented, "I am delighted to be joining CytoSorbents at this
critical juncture as it accelerates commercialization of CytoSorb®.I will add
my financial leadership and management expertise as part of this excellent
team and begin to contribute to the international growth initiatives that are
underway, help drive a rapid growth strategy, and create significant
shareholder value."

"Kathy has a proven track record of driving growth at successful companies,"
stated Al Kraus, CytoSorbents' Chairman of the Board. "In addition, she now
rounds out our already strong expanded management team, bringing valuable
experience in corporate finance, operations, governance, and compliance to the
Company.She will undoubtedly make some outstanding contributions to the
Company, and we are pleased to have her on board."

Dr. Phillip Chan, Chief Executive Officer of CytoSorbents, remarked, "We are
very excited to welcome Kathy as CFO.Throughout her career, she has
impressively managed and helped finance a variety of rapid growth companies,
some extremely complex, and has developed an outstanding background in
manufacturing.This is an excellent match for our current and future needs.In
addition, her personality, energy and enthusiasm, coupled with her extensive
experience, business acumen and skills, is an excellent fit for our management
team, and will contribute to the success of our long-term strategic plan."

Dr. Chan added, "The Company and the Board of Directors also extends its
sincere appreciation to Mr. Ronald Berger for his excellent performance and
dedication as Interim CFO for the past several months."

About CytoSorbents Corporation

CytoSorbents Corporation is a critical care focused therapeutic device company
using blood purification to control a poorly-regulated immune system and fight
multi-organ failure in life-threatening illnesses.Its purification technology
is based on biocompatible, highly porous polymer beads that can actively
remove toxic substances from blood and other bodily fluids by pore capture and
adsorption.CytoSorb®, the Company's flagship product, is approved in the
European Union as a safe and effective extracorporeal cytokine filter,
designed to reduce the "cytokine storm" that could otherwise cause massive
inflammation, organ failure and death in common critical illnesses such as
sepsis, burn injury, trauma, lung injury, and pancreatitis.These are
conditions where the mortality is extremely high, yet no effective treatments
exist. Additional information is available for download on the Company's
website: http://www.cytosorbents.com.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for
the safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Forward-looking statements in this press
release are not promises or guarantees and are subject to risks and
uncertainties that could cause our actual results to differ materially from
those anticipated. These statements are based on management's current
expectations and assumptions and are naturally subject to uncertainty and
changes in circumstances. We caution you not to place undue reliance upon any
such forward-looking statements. Actual results may differ materially from
those expressed or implied by the statements herein.Risk factors are detailed
in the Company's Form 10-K filed with the SEC on April 3, 2013, which is
available athttp://www.sec.gov.

CONTACT: Company Contact:
         CytoSorbents Corporation
         Dr. Phillip Chan
         Chief Executive Officer
         (732) 329-8885 ext. *823
         pchan@cytosorbents.com
        
         Investor Contact:
         Alliance Advisors, LLC
         Alan Sheinwald
         (914) 669-0222
         asheinwald@allianceadvisors.net
        
         Valter Pinto
         (914) 669-0222 x201
         valter@allianceadvisors.net
        
         Media Contact:
         JQA Partners
         Jules Abraham
         (917) 885-7378
         jabraham@jqapartners.com
 
Press spacebar to pause and continue. Press esc to stop.